CD206-NAMPT inhibitor-based antibody drug conjugate (Bayer)

N/A

Report date: 2025/01/26 16:42:59

Base Information

Drug NameCD206-NAMPT inhibitor-based antibody drug conjugate (Bayer)

Drug Alias NameCD206-NAMPT inhibitor-based ADC (Bayer)NAMPT inhibitor-based ADC (Bayer)CD206-NAMPT-ADC

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionNicotinamide phosphoribosyltransferase inhibitors

TargetsNicotinamide phosphoribosyltransferase

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Active CompaniesBayer AG

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

ATC CodeN/A